How Pharma Sales Reps Use Claims Data, Prescribing Analytics, and Open Payments to Target the Right Physicians

The Targeting Gap That's Costing Pharma Field Teams Selling Time

U.S. pharmaceutical companies spent more than $20 billion marketing directly to healthcare professionals in 2016 alone, according to research published in JAMA — and industry investment in HCP marketing has only grown since. Yet despite that scale of spend, the core challenge facing every pharma field team remains unchanged: knowing which of the roughly 9 million licensed physicians in the United States are actually worth calling on, what they're prescribing right now, and whether your product fits what they're actively treating in practice.

The answer has always been data. The shift is in what data is now available, how granularly it maps to individual clinicians, and how quickly commercial teams can act on it. Three data types have become foundational to modern pharma targeting: claims data, prescribing analytics derived from those claims, and Open Payments records from the CMS Sunshine Act program. Each one answers a different question about a physician's commercial potential. Understanding them — and how they work together — is what separates a field team making data-informed decisions from one still working off outdated contact lists.

What Claims Data Actually Tells a Pharma Sales Rep

Claims data begins at a concrete level: a record is generated every time a prescription is dispensed or a medical procedure is billed. Across the U.S. healthcare system, those records accumulate into a volume that makes individual physician behavior observable at scale. According to the IQVIA Institute's report on medicine use in the U.S., Americans filled approximately 6.6 billion prescriptions in 2022 — each one a data point reflecting a clinical decision made by a specific prescriber at a specific moment in time.

For pharma commercial teams, claims data breaks into two categories. Rx claims — prescription drug claims — show which medications a physician is writing, at what volumes, and for which diagnoses. These records reveal not just that a physician prescribes in your drug class, but exactly how much they prescribe, how that volume compares to peers in the same specialty and geography, and whether that activity is trending up or down. CMS Medicare Part D prescribing data, for example, provides publicly available records of what Medicare-eligible physicians prescribe across thousands of drug categories — one of several data sources that feed into comprehensive commercial claims databases.

Procedure claims serve a parallel function for medical device companies. What surgical or interventional procedures does a clinician perform, at what volume, and at which facilities? A spine surgeon's procedure mix tells a device company everything it needs to know about whether that surgeon belongs in the top decile of targets — before a single cold call is made.

The practical value for field reps is that claims data converts territory planning from a guessing exercise into a precision activity. Rather than calling on physicians based on specialty alone, a rep can identify clinicians in the top quartile of prescribers in a therapeutic area, ranked by volume, within a defined geography. G LNK's claims analytics provides access to 3B+ Rx claims and 5B+ procedure claims, making it possible to build a prioritized targeting list for any territory in minutes.

How Prescribing Analytics Turns Raw Claims into Call Intelligence

Raw claims data tells you what happened. Prescribing analytics tells you what it means — and, critically, when to act on it.

The gap between those two outputs is where most of the commercial value lives. A physician who wrote 200 scripts for a beta-blocker last quarter is a data point. A physician who wrote 200 scripts for a competitor's beta-blocker, maintains a growing hypertension panel, wrote 50 scripts for your drug in the prior quarter before switching, and has had no documented engagement with your field team in 90 days — that is a decision-ready target. That insight only emerges when raw claims are processed through analytics that reveal competitive dynamics, trend direction, patient mix, and engagement history simultaneously.

Three analytics capabilities have become standard practice for commercial teams with access to claims-based platforms. Market share analysis shows what percentage of a physician's total prescriptions in a given drug class go to your product versus competitors — the denominator being their complete prescribing activity in that class, not just the prescriptions you know about. Switch analytics identifies when a physician begins moving patients from one therapy to another, which is typically the highest-value window for rep engagement. A rep who reaches a prescriber in the first four to six weeks of a prescribing shift has a meaningfully different conversation than one who arrives six months after the pattern is established. Trend detection monitors volume changes in near-real time, allowing commercial teams to respond to competitive dynamics months before they appear in quarterly syndicated reports.

According to McKinsey's analysis of biopharma commercial model transformation, organizations that integrate real-world data into field force operations consistently outperform those relying on lagged, aggregated market data — a gap that compounds over product lifecycle. G LNK's HCP Profiles integrate prescribing analytics directly into clinician profiles, so a field rep can review a physician's prescribing trajectory alongside their specialty, affiliations, and procedure volumes without switching between systems.

Open Payments Data: The Compliance Layer That Also Drives Commercial Strategy

The CMS Open Payments program was established under the Physician Payments Sunshine Act to bring transparency to financial relationships between the pharmaceutical and medical device industries and healthcare professionals. Every year, CMS publishes detailed records of payments — speaker fees, consulting fees, research grants, meals, travel, and other transfers of value — between life sciences companies and physicians and teaching hospitals. The 2022 program year dataset captures more than $12 billion in reportable payments across millions of individual records, representing one of the most comprehensive public datasets on industry-physician financial relationships in the world.

For compliance teams, the value is straightforward: cross-referencing your payment records against CMS data allows you to verify accuracy, identify discrepancies, and prepare for regulatory review before it happens rather than after. But the commercial intelligence value of Open Payments data is frequently underused by field teams, and it's equally significant.

The payment records reveal which physicians have an existing, documented relationship with your therapeutic area. A physician who has served as a paid speaker for a competitor's product in the same drug class has already demonstrated engagement with the commercial side of medicine in that category. They understand the clinical landscape, have likely formed strong opinions about available therapies, and are almost certainly a high-value target for your team to understand and engage. Reaching that physician with a well-informed, differentiated message is a categorically different sales call than a cold approach to someone with no documented history.

Open Payments data also enables structured KOL identification. A clinician who appears across multiple company payment records as a consultant, researcher, and advisory board participant in a given specialty is likely influencing prescribing behavior well beyond their own patient panel. Mapping these relationships — which physicians are receiving payments from which companies, for which activities — gives commercial and medical affairs teams a data-driven basis for KOL strategy rather than relying on reputation or referral networks alone.

G LNK tracks $11B+ in Open Payments and FMV data, integrated directly into clinician profiles so compliance officers and commercial teams work from the same underlying records rather than maintaining separate systems with separate reconciliation workflows.

How the Three Data Types Work Together: A Practical Targeting Workflow

The real competitive advantage emerges when claims data, prescribing analytics, and Open Payments records are layered together into a single view of a physician. Each data type answers a different question; combined, they create a picture of a physician's commercial potential and engagement context that no single source can provide.

The table below shows what each data type reveals and how commercial teams use them at different stages of the targeting and engagement cycle.

A field rep preparing to target a high-volume rheumatologist, for example, would start by reviewing Rx claims to confirm prescribing volume in the relevant therapeutic class. They would run market share analytics to understand what proportion of that volume is going to competitor products versus their own drug. They would check Open Payments records to identify any prior relationship between this physician and industry. And they would review trend data to determine whether prescribing activity is growing, contracting, or shifting. That pre-call profile — previously requiring hours of manual research across disconnected sources — now takes minutes on a platform that integrates all four data types.

Why Fragmented Data Stacks Cost More Than the Vendors They Add

The challenge most commercial teams face is not that this data doesn't exist — it is that it's scattered. Rx claims purchased from one vendor. Procedure data from a second. Open Payments exports managed by the compliance team in a separate spreadsheet. Analytics built in a third tool. CRM records that reflect none of the above because no one has set up the integration.

Each additional data source adds licensing cost, creates reconciliation work between sources with different physician identifiers and update cadences, and introduces lag between when data is generated and when a rep can act on it. Research from Deloitte's global life sciences outlook consistently identifies data fragmentation as a primary barrier to commercial efficiency in pharma — a finding that aligns with what commercial leaders report across companies of every size.

The operational case for a unified data platform is measurable. When claims analytics, prescribing trends, Open Payments records, and HCP profile data live in one place, reps spend less time assembling a pre-call picture and more time applying it. ZS research on field force commercial operations documents the direct relationship between rep time spent on data assembly versus selling activities — and the teams that have closed that gap through integrated platforms consistently show better territory coverage efficiency and higher HCP engagement rates. When that unified platform also offers native CRM integrations — connecting enriched HCP data and analytics directly into Salesforce or HubSpot — the manual transfer step is eliminated entirely, and data-driven targeting becomes part of the workflow rather than a separate research process.

A healthcare commercial intelligence platform like G LNK consolidates all of this into a single interface: 9.2M+ HCP profiles, 3B+ Rx claims, 5B+ procedure claims, $11B+ in Open Payments and FMV data, and 68K+ institutional records, with direct CRM integrations and territory analytics built in. That is a different operational model than managing four separate data vendors — and the difference shows up in how quickly commercial teams can translate market intelligence into field action.

What Every Pharma Commercial Team Should Know Before Their Next Territory Review

The three data types covered in this article — claims data, prescribing analytics, and Open Payments records — are not new. What has changed is the availability and integration of these data sets, the speed at which they can be analyzed, and the accessibility of platforms that put them in front of field teams rather than requiring a dedicated data science team to operationalize them.

The commercial teams building durable targeting advantages today are the ones that have moved from relying on any single data type to working from all three simultaneously. Claims data gives you the map. Prescribing analytics tells you where the opportunities are moving. Open Payments tells you the relationship context that determines how to show up. Together, they make every territory review more precise and every field call more informed.

Start a free Health Explorer trial to search G LNK's claims analytics and HCP data across your territory, or see G LNK in action to walk through how the platform works for your specific therapeutic area and commercial workflow.

You Might Also Like

• How Pharma Commercial Teams Use Claims Data and Prescribing Analytics to Build Smarter Territory Plans

• What Is Healthcare Commercial Intelligence? The Complete Guide for Pharma and MedTech Teams

• Best HCP Data Providers in 2026: How to Choose the Right Healthcare Provider Database

• IQVIA Alternatives for Mid-Market Pharma: Affordable Healthcare Data Platforms with Enterprise-Grade Coverage